Google
EVMN 株価分析 — Evommune, Inc. (Healthcare >> Biotechnology)
EVMN に関するよくある質問
EVMNのROE（自己資本利益率）は？
Evommune, Inc.のROEは-24.95%です。
EVMNの配当利回りは？
Evommune, Inc.の配当利回りは0.00%です。
EVMNの品質スコア（Quality Score）は？
当社のAIはEVMNの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
EVMNは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
EVMNはどのセクターに属しますか？
Evommune, Inc.はHealthcare >> Biotechnologyセクターに分類されます（NYSE市場）
EVMN AI Analysis Summary
Our AI summary for EVMN: Evommune, Inc. (NYSE), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -24.95%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 11.25
Price
-0.10
(-0.88%)
Day Change
|
|
|---|
EVMN, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 11.25 |
| PBV / Sector |
1.34 / 5.20
GOOD
|
| Earning Per Share | -2.09 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
8.42 M
|
| Average 1W Daily Value |
4.43 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:48 |
| Symbol | EVMN |
| Name | EVOMMUNE, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE |
| Listed Shares | 36.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 408.81 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1891 Page Mill Road, Palo Alto, CA, United States, 94304
Phone: (925) 247-4481
Website: https://www.evommune.com
Sector: Healthcare >> Biotechnology
Description: Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
